… the pathogenesis of APS. Consequently, although anticoagulation remains the standard
treatment for thrombotic … are involved in the pathogenesis of APS has significant implications for …

… thrombotic events. In case of aPL positivity without previous thrombotic events, the treatment
is mainly focused on reduction of additional vascular risk factors, while treatment of patients …

… to treatment and secondary prevention of thromboembolism are highlighted in table 2. Vitamin
K antagonists are the recommended treatment for thrombotic antiphospholipid syndrome. …

… Antiphospholipid syndrome is a distinct disorder with the clinical features of recurrent
thrombosis … Its serological marker is the presence of antiphospholipid antibodies in the blood of …

… the presence of additional thrombotic risk factors. Current standard treatment for unprovoked
thrombosis is long-term warfarin or other vitamin K antagonist therapy. Treatment to prevent …

… In patients with the antiphospholipid syndrome (APS), the presence of a group of pathogenic
autoantibodies called antiphospholipid antibodies causes arteriovenous thrombosis and …

The antiphospholipid syndrome (APS), a systemic autoimmune disease characterized by a …
vascular thrombosis and/or obstetric morbidity, is caused by the presence of antiphospholipid …

… The antiphospholipid syndrome is characterized by antibodies directed against … ,
culminating in thrombotic events and pregnancy morbidity that further define the syndrome. The …

… risk of thrombosis. … thrombotic risk is unknown. In this review, we will critically discuss
what is known and what is debatable on the pathophysiology of antiphospholipid syndrome…

… The antiphospholipid syndrome (APS) is a systemic autoimmune disease and the patients
… antiphospholipid antibodies (aPL).[1] [2] [3] APS patients are at high risk for both thrombosis …